Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes

Seok Kang Eun, Young Park So, Jin Kim Hyeong, Sik Kim Chul, Woo Ahn Chul, Soo Cha Bong, Sungkil Lim, Mo Nam Chung, Chul Lee Hyun

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Objective: The aim of this study was to examine the effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) γ2 gene on the response to rosiglitazone in patients with type 2 diabetes mellitus. Methods: A total of 198 patients with type 2 diabetes mellitus were treated with rosiglitazone (4 mg/d) for 12 weeks without a change in previous medications. All patients were genotyped for the PPARγ2 Pro12Ala polymorphism. Results: The Ala12 allele frequency was 0.04. Of the 198 patients, 183 had the Pro12Pro genotype and 15 had the Pro12Ala genotype. The Ala12Ala genotype was not observed. The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 ± 27.8 mg/dL versus 24.3 ± 41.9 mg/dL, P = .026). In addition, the decrease in hemoglobin A1c level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41% ± 1.47% versus 0.57% ± 1.16%, P = .015). There was a significant difference in the response rate to rosiglitazone treatment between the Pro12Pro group and the Pro12Ala variant group (43.72% versus 86.67%, P = .002). Conclusion: Patients with the Pro12Ala genotype in the PPARγ2 gene had a better therapeutic response to rosiglitazone than did patients with the Pro12Pro genotype. The genetic variations in the PPARγ2 gene can affect the response to rosiglitazone treatment in patients with type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)202-208
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume78
Issue number2
DOIs
Publication statusPublished - 2005 Aug 1

Fingerprint

rosiglitazone
Peroxisome Proliferator-Activated Receptors
Type 2 Diabetes Mellitus
Genotype
Genes
Alleles
Gene Frequency
Fasting
Hemoglobins

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Eun, Seok Kang ; So, Young Park ; Hyeong, Jin Kim ; Chul, Sik Kim ; Chul, Woo Ahn ; Bong, Soo Cha ; Lim, Sungkil ; Chung, Mo Nam ; Hyun, Chul Lee. / Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. In: Clinical Pharmacology and Therapeutics. 2005 ; Vol. 78, No. 2. pp. 202-208.
@article{c2b22b9261a84435bb3af1846d32637e,
title = "Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes",
abstract = "Objective: The aim of this study was to examine the effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) γ2 gene on the response to rosiglitazone in patients with type 2 diabetes mellitus. Methods: A total of 198 patients with type 2 diabetes mellitus were treated with rosiglitazone (4 mg/d) for 12 weeks without a change in previous medications. All patients were genotyped for the PPARγ2 Pro12Ala polymorphism. Results: The Ala12 allele frequency was 0.04. Of the 198 patients, 183 had the Pro12Pro genotype and 15 had the Pro12Ala genotype. The Ala12Ala genotype was not observed. The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 ± 27.8 mg/dL versus 24.3 ± 41.9 mg/dL, P = .026). In addition, the decrease in hemoglobin A1c level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41{\%} ± 1.47{\%} versus 0.57{\%} ± 1.16{\%}, P = .015). There was a significant difference in the response rate to rosiglitazone treatment between the Pro12Pro group and the Pro12Ala variant group (43.72{\%} versus 86.67{\%}, P = .002). Conclusion: Patients with the Pro12Ala genotype in the PPARγ2 gene had a better therapeutic response to rosiglitazone than did patients with the Pro12Pro genotype. The genetic variations in the PPARγ2 gene can affect the response to rosiglitazone treatment in patients with type 2 diabetes mellitus.",
author = "Eun, {Seok Kang} and So, {Young Park} and Hyeong, {Jin Kim} and Chul, {Sik Kim} and Chul, {Woo Ahn} and Bong, {Soo Cha} and Sungkil Lim and Chung, {Mo Nam} and Hyun, {Chul Lee}",
year = "2005",
month = "8",
day = "1",
doi = "10.1016/j.clpt.2005.04.013",
language = "English",
volume = "78",
pages = "202--208",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. / Eun, Seok Kang; So, Young Park; Hyeong, Jin Kim; Chul, Sik Kim; Chul, Woo Ahn; Bong, Soo Cha; Lim, Sungkil; Chung, Mo Nam; Hyun, Chul Lee.

In: Clinical Pharmacology and Therapeutics, Vol. 78, No. 2, 01.08.2005, p. 202-208.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes

AU - Eun, Seok Kang

AU - So, Young Park

AU - Hyeong, Jin Kim

AU - Chul, Sik Kim

AU - Chul, Woo Ahn

AU - Bong, Soo Cha

AU - Lim, Sungkil

AU - Chung, Mo Nam

AU - Hyun, Chul Lee

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Objective: The aim of this study was to examine the effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) γ2 gene on the response to rosiglitazone in patients with type 2 diabetes mellitus. Methods: A total of 198 patients with type 2 diabetes mellitus were treated with rosiglitazone (4 mg/d) for 12 weeks without a change in previous medications. All patients were genotyped for the PPARγ2 Pro12Ala polymorphism. Results: The Ala12 allele frequency was 0.04. Of the 198 patients, 183 had the Pro12Pro genotype and 15 had the Pro12Ala genotype. The Ala12Ala genotype was not observed. The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 ± 27.8 mg/dL versus 24.3 ± 41.9 mg/dL, P = .026). In addition, the decrease in hemoglobin A1c level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41% ± 1.47% versus 0.57% ± 1.16%, P = .015). There was a significant difference in the response rate to rosiglitazone treatment between the Pro12Pro group and the Pro12Ala variant group (43.72% versus 86.67%, P = .002). Conclusion: Patients with the Pro12Ala genotype in the PPARγ2 gene had a better therapeutic response to rosiglitazone than did patients with the Pro12Pro genotype. The genetic variations in the PPARγ2 gene can affect the response to rosiglitazone treatment in patients with type 2 diabetes mellitus.

AB - Objective: The aim of this study was to examine the effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) γ2 gene on the response to rosiglitazone in patients with type 2 diabetes mellitus. Methods: A total of 198 patients with type 2 diabetes mellitus were treated with rosiglitazone (4 mg/d) for 12 weeks without a change in previous medications. All patients were genotyped for the PPARγ2 Pro12Ala polymorphism. Results: The Ala12 allele frequency was 0.04. Of the 198 patients, 183 had the Pro12Pro genotype and 15 had the Pro12Ala genotype. The Ala12Ala genotype was not observed. The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 ± 27.8 mg/dL versus 24.3 ± 41.9 mg/dL, P = .026). In addition, the decrease in hemoglobin A1c level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41% ± 1.47% versus 0.57% ± 1.16%, P = .015). There was a significant difference in the response rate to rosiglitazone treatment between the Pro12Pro group and the Pro12Ala variant group (43.72% versus 86.67%, P = .002). Conclusion: Patients with the Pro12Ala genotype in the PPARγ2 gene had a better therapeutic response to rosiglitazone than did patients with the Pro12Pro genotype. The genetic variations in the PPARγ2 gene can affect the response to rosiglitazone treatment in patients with type 2 diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=23444457610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444457610&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2005.04.013

DO - 10.1016/j.clpt.2005.04.013

M3 - Article

VL - 78

SP - 202

EP - 208

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -